BZW2 Knockout HAP1 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population in the HAP1 human haploid cell line, engineered to disrupt the BZW2 gene and provide a loss-of-function model for studying its biological roles. The polyclonal format consists of a heterogeneous pool of cells carrying diverse CRISPR-induced mutations at the BZW2 locus, enabling robust bulk phenotype analysis while minimizing clonal artifacts.
HAP1 cells are a near-haploid human cell line originally derived from the KBM-7 chronic myeloid leukemia line. Because they are haploid for most chromosomes (except a small portion of chromosome 8 and the sex chromosomes), loss-of-function mutations can be introduced in a single allele, leading to unambiguous knockout phenotypes without the need for homozygous editing. This genetic simplicity has made HAP1 a premier model for functional genomics, haploid genetic screens, and drug-gene interaction studies.
BZW2 encodes an eIF5-mimic protein that plays a critical role in translation initiation by governing start codon selection and modulating ternary complex formation. It is a key node in the eIF2 signaling pathway and the integrated stress response, directly interacting with the eIF2 complex (subunits ??, ??, ??), the eIF3 complex, and eIF5. Its activity is tightly regulated by upstream signals including ATF4 transcription factor induction and mTOR signaling, and it in turn influences downstream processes such as global protein synthesis and stress-responsive translation. Through these interactions, BZW2 helps fine-tune the cellular proteome in response to nutrient and stress conditions.
In the HAP1 background, disruption of BZW2 allows direct assessment of its function in translational control, where the haploid genetics provide a clean loss-of-function system. Loss of BZW2 is expected to alter start codon selection fidelity and perturb stress-induced translation, offering a model to dissect the integrated stress response and its cross-talk with oncogenic mTOR-ATF4 signaling. This is particularly relevant for understanding translational reprogramming in chronic myeloid leukemia and other cancers that rely on adaptive protein synthesis.
Research applications encompass translation regulation studies, cancer biology, stress response research, and drug target validation. Suitable assays include polysome profiling to assess ribosome loading, dual-luciferase reporter assays for uORF-mediated control, western blot for eIF2?? phosphorylation status, and ribosome footprinting coupled with RNA-seq for translatome-wide analysis. These approaches enable detailed mechanistic studies of the BZW2-eIF2-ATF4 axis and stress-responsive translation. For further information, please contact Ascent Research.
